Security
Arcadia Biosciences, Inc. Common Stock · RKDA
RKDANASDAQCommon stockCurrentCIK 1469443Updated Oct 4, 2026
RKDA price & chart
Loading TradingView…
NASDAQ:RKDA on TradingView ↗About the company
Since 2002, Arcadia Biosciences (Nasdaq: RKDA) has been innovating high-value, healthy ingredients to meet consumer demands for healthier choices. With its roots in agricultural innovation, Arcadia cultivates next-generation wellness products. For more information, visit www.arcadiabio.com.
In the news
Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules ↗
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HRZN, RKDA, HNI on Behalf of Shareholders News provided by Halper Sadeh LLP Oct 09, 2025, 11:46 ET Share this article Share to X Share this article Share to X NEW YORK , Oct. 9, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm ↗
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OLO, FUBO, RKDA, NSC on Behalf of Shareholders News provided by Halper Sadeh LLP Aug 01, 2025, 20:49 ET Share this article Share to X Share this article Share to X NEW YORK , Aug. 1, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights la ↗
Recent filings
S-8 filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
4 filing
4 filing
4 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 6,546,000Source | 13,517,000Source | 19,705,000Source | 28,922,000Source |
| Property, Plant and Equipment, NetUSD | 8,000Source | 41,000Source | 384,000Source | 704,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 39,000Source | 39,000Source | 39,000Source | 40,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 259,000Source | 4,242,000Source | 6,518,000Source | 20,644,000Source |
| Inventory, NetUSD | 1,212,000Source | 904,000Source | 1,958,000Source | 2,571,000Source |
| Assets, CurrentUSD | 6,356,000Source | 9,242,000Source | 14,972,000Source | 25,398,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 156,000Source | 931,000Source | 807,000Source | 809,000Source |
| Operating Lease, Right-of-Use AssetUSD | 0Source | 137,000Source | 792,000Source | 1,848,000Source |
| Other Assets, NoncurrentUSD | 143,000Source | 92,000Source | 164,000Source | 165,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 2,406,000Source | 7,294,000Source | 7,002,000Source | 8,022,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 65,000Source | 65,000Source | 65,000Source | 65,000Source |
| Retained Earnings (Accumulated Deficit)USD | -281,217,000Source | -278,878,000Source | -271,840,000Source | -257,859,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | — | 0Source | 101,000Source | — |
| Stockholders' Equity Attributable to ParentUSD | — | 6,223,000Source | 12,841,000Source | 21,033,000Source |
| Additional Paid in Capital, Common StockUSD | 285,292,000Source | 285,036,000Source | 284,515,000Source | 278,827,000Source |
| Liabilities and EquityUSD | 6,546,000Source | 13,517,000Source | 19,705,000Source | 28,922,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,059,000Source | 2,563,000Source | 3,590,000Source | 4,209,000Source |
| Operating Lease, Liability, CurrentUSD | 0Source | 155,000Source | 852,000Source | 1,010,000Source |
| Operating Lease, Liability, NoncurrentUSD | — | 0Source | 155,000Source | 1,007,000Source |
| Other Liabilities, NoncurrentUSD | 0Source | 2,000,000Source | 2,000,000Source | 2,000,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | 0Source | -138,000Source | -133,000Source |
| Additional Financial Items | ||||
| Short-term InvestmentsUSD | 4,304,000Source | 0Source | 5,124,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -2,339,000Source | -7,038,000Source | -13,986,000Source | -15,612,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 234,000Source | 512,000Source | 717,000Source | 1,106,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | -165,000Source | 762,000Source | -184,000Source | -592,000Source |
| Increase (Decrease) in InventoriesUSD | 308,000Source | -550,000Source | 2,419,000Source | -1,118,000Source |
| Deferred Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -4,739,000Source | -9,627,000Source | -15,294,000Source | -13,977,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | 0Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 750,000Source | 7,342,000Source | -4,344,000Source | 1,417,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 0Source | 16,000Source | 5,000Source | 72,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 6,000Source | 9,000Source | 5,512,000Source | 4,519,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -3,983,000Source | -2,276,000Source | -14,126,000Source | -8,041,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | 0Source | 1,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 234,000Source | 512,000Source | 717,000Source | 1,106,000Source |
| Amortization of Intangible AssetsUSD | — | — | 0Source | 40,000Source |
| Debt and Equity Securities, Realized Gain (Loss)USD | — | — | — | 0Source |
| DepreciationUSD | 32,000Source | 58,000Source | 287,000Source | 439,000Source |
| Equity Method Investment, Realized Gain (Loss) on DisposalUSD | — | — | 0Source | 1,138,000Source |
| Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber PropertyUSD | 0Source | 65,000Source | 40,000Source | 314,000Source |
| Gain (Loss) on Disposition of Intangible AssetsUSD | 750,000Source | 4,000,000Source | — | 0Source |
| Gain (Loss) on Disposition of BusinessUSD | — | — | — | 0Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | 0Source | 40,000Source | 314,000Source |
| Goodwill, Impairment LossUSD | — | — | — | 0Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | 0Source | 404,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -2,339,000Source | -4,317,000Source | -13,165,000Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -821,000Source | — |
| Income Tax Expense (Benefit)USD | 8,000Source | 8,000Source | 8,000Source | 14,000Source |
| Inventory Write-downUSD | 0Source | 154,000Source | 444,000Source | 2,471,000Source |
| Net Income (Loss) Attributable to ParentUSD | -2,339,000Source | -7,038,000Source | -13,981,000Source | -15,376,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | 0Source | -5,000Source | -236,000Source |
| Other Nonoperating Income (Expense)USD | 2,309,000Source | 31,000Source | 48,000Source | 33,000Source |
| Payments to Acquire InvestmentsUSD | — | 0Source | 7,525,000Source | — |
| Proceeds from Contributed CapitalUSD | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | 7,000Source |
| Realized Investment Gains (Losses)USD | 1,067,000Source | — | — | — |
| Unrealized Gain (Loss) on InvestmentsUSD | 1,237,000Source | — | — | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 4,858,000Source | 5,045,000Source | 5,330,000Source | 9,956,000Source |
| Cost of RevenueUSD | 3,098,000Source | 2,963,000Source | 3,300,000Source | 9,802,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | 7,001,000Source | 9,641,000Source | 14,508,000Source | 18,048,000Source |
| Operating Income (Loss)USD | -2,500,000Source | -3,648,000Source | -13,938,000Source | -18,815,000Source |
| Other Nonoperating Income (Expense)USD | 2,309,000Source | 31,000Source | 48,000Source | 33,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -2,331,000Source | -4,309,000Source | -13,157,000Source | -15,598,000Source |
| Income Tax Expense (Benefit)USD | 8,000Source | 8,000Source | 8,000Source | 14,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | 0Source | -5,000Source | -236,000Source |
| Net Income (Loss) Attributable to ParentUSD | -2,339,000Source | -7,038,000Source | -13,981,000Source | -15,376,000Source |
| Earnings Per Share, BasicUSD per share | -1.71Source | -5.17Source | — | -25.65Source |
| Earnings Per Share, DilutedUSD per share | -1.71Source | -5.17Source | — | -25.65Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,368,057Source | 1,363,303Source | 1,236,934Source | 599,389Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,368,057Source | 1,363,303Source | 1,236,934Source | 599,389Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | — | — | 0Source | 40,000Source |
| Costs and ExpensesUSD | 7,358,000Source | 8,693,000Source | 19,268,000Source | 28,771,000Source |
| Current Income Tax Expense (Benefit)USD | 8,000Source | 8,000Source | 8,000Source | 14,000Source |
| Debt and Equity Securities, Realized Gain (Loss)USD | — | — | — | 0Source |
| Goodwill, Impairment LossUSD | — | — | — | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -2,331,000Source | -7,030,000Source | -13,978,000Source | -15,598,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | -2,339,000Source | -4,317,000Source | -13,165,000Source | — |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | -1.71Source | -3.17Source | -10.64Source | — |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | -1.71Source | -3.17Source | -10.64Source | — |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -821,000Source | — |
| Interest Income (Expense), NetUSD | 221,000Source | 782,000Source | 695,000Source | 289,000Source |
| Marketing and Advertising ExpenseUSD | — | 51,000Source | — | — |
| Realized Investment Gains (Losses)USD | 1,067,000Source | — | — | — |
| Research and Development ExpenseUSD | 9,000Source | 53,000Source | 1,387,000Source | 1,509,000Source |
Offerings
Registration 333-297072
Registration 333-292993
Registration 333-284972
Filing attachments
rkda-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 rkda-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Arcadia Biosciences (RKDA) Announces Second Quarter and First Half 2026 Financial Results and Business Highlights - Net cash used in operating activities only $319K in the second quarter - - Arcadia closes $4 million private placement; ends second quarter with $4.2 million in cash - - July monthly Zola® sales top $740K; exceed $1 million through first week of August - DALLAS, Texas (August 13, 2026) - Arcadia Biosciences, Inc.® (Na…
Read attachment ↗rkda-ex99_2.htm · 8-K · 2026-08-13
EX-99.2 3 rkda-ex99_2.htm EX-99.2 EX-99.2 Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) June 30, 2026 December 31, 2025 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── Assets Current assets: Cash and cash …
Read attachment ↗rkda-ex4_1.htm · 8-K · 2026-06-15
EX-4.1 2 rkda-ex4_1.htm EX-4.1 EX-4.1 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO …
Read attachment ↗rkda-ex4_2.htm · 8-K · 2026-06-15
EX-4.2 3 rkda-ex4_2.htm EX-4.2 EX-4.2 Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO …
Read attachment ↗rkda-ex4_3.htm · 8-K · 2026-06-15
EX-4.3 4 rkda-ex4_3.htm EX-4.3 EX-4.3 Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO …
Read attachment ↗rkda-ex4_4.htm · 8-K · 2026-06-15
EX-4.4 5 rkda-ex4_4.htm EX-4.4 EX-4.4 Exhibit 4.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO …
Read attachment ↗